ETF Monitors

thumbnail

Weekly ETF Monitor for week ending 1 November 2019

This week's highlights

  • The U.S. Equity Market hit fresh highs last week, which saw the iShares S&P 500 AUD Hedged ETF (IHVV) finish the week 1.5% up.

  • Globally, the healthcare sector had a strong week, with BetaShares Global Healthcare ETF (Hedged) (DRUG) up 2.6% and ETFS S&P Biotech ETF (CURE) returning 1.6% for the week.

  • Australian financials had a weak week. VanEck Vectors Australian Banks ETF (MVB) was down 3.4%, while SPDR S&P/ASX 200 Financials ex A-REIT Fund (OZF) and BetaShares S&P/ASX 200 Financials Sector ETF (QFN) were both down 3.1%.

  • Total flows into domestically domiciled ETFs were $258m, while outflows totalled $62m. QPON and FUEL saw the largest inflows for the week, followed by HBRD and a mix of equity funds. IHCB and ILB saw the bulk of outflows for the week.

  • VAS was the most traded fund last week, followed by FUEL and QPON.

  • The best performing ETF Securities fund was the ETFS S&P Biotech ETF (CURE). This fund offers investors equally-weighted exposure to the U.S. biotechnology sub-sector. It captures returns from firms that focus on the research and development of innovative drugs and treatments. The performance of individual biotechnology companies can be speculative and is highly dependent on FDA approvals and M&A activity. CURE offers exposure to advances in the sector, while diversifying the single-name risk across more than 120 companies.